TRAW
Traws Pharma·NASDAQ
--
--(--)
--
--(--)
3.88 / 10
Netural
Analyst coverage is minimal with only one Strong Buy rating and a historical win-rate of 0.0%, indicating weak consensus. Fund-flow data show a good overall score of 7.76/10, yet large and extra-large block trends are negative, hinting at institutional skepticism despite some positive medium-term inflows.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-03
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for TRAW?
- TRAW holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.88/10 (Netural).
